title: Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation.
abstract: Interferon-alpha (IFN-alpha) is a pleotropic cytokine that has clinical activity against a wide variety of malignancies, including multiple myeloma (MM). In vitro, IFN-alpha has diverse effects on both normal and malignant cells, however, the exact mechanisms responsible for its clinical anti-tumour activity remain unclear. We found that IFN-alpha inhibited MM cell proliferation in association with cell cycle arrest at G1 and limited the clonogenic growth of both MM cell lines and primary patient specimens. At the doses tested, IFN-alpha was not cytotoxic, but induced terminal plasma cell differentiation resulting in the loss of clonogenicity. These activities were markedly enhanced by the major MM growth factor interleukin 6 (IL-6). Moreover, IL-6 was required for this process, as neutralizing antibodies against IL-6 inhibited the effects of IFN-alpha. IL-6 also induced MM cell terminal differentiation when combined with a second, unrelated, antiproliferative agent bryostatin-1, suggesting that its differentiating activities are preferentially enhanced in the presence of agents that inhibit cell cycling. These results suggest that the differentiating activities of IFN-alpha may play a role in its clinical antimyeloma activity and provide the rationale for clinical differentiation therapy in MM.
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA. matsuwi@jhmi.edu
authors.forename: William
authors.initials: W
authors.lastname: Matsui
authors.forename: Carol Ann
authors.initials: CA
authors.lastname: Huff
authors.forename: Milada
authors.initials: M
authors.lastname: Vala
authors.forename: James
authors.initials: J
authors.lastname: Barber
authors.forename: B Douglas
authors.initials: BD
authors.lastname: Smith
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Jones
mesh_terms: D000704:Analysis of Variance; D017209:Apoptosis / Q000187:drug effects; D054713:Bryostatins; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002999:Clone Cells; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D016898:Interferon-alpha / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000276:immunology / Q000627:therapeutic use*; D007783:Lactones / Q000494:pharmacology; D018942:Macrolides; D008934:Mitogens / Q000494:pharmacology; D009101:Multiple Myeloma / Q000628:therapy*; D014407:Tumor Cells, Cultured
chemical_list: D054713:Bryostatins; D007106:Immune Sera; D016898:Interferon-alpha; D015850:Interleukin-6; D007783:Lactones; D018942:Macrolides; D008934:Mitogens; C046785:bryostatin 1